Description
CAS NO: 863288-34-0 Molecular Formula: C152H252N44O42 Molecular Weight: 3367.9 g/mol Appearance: white powder Storage: 2-8° Purity: ≥99%
PURITY TESTING:
Verify our latest purity tests from Finnrick
Screenshot
CJ_20250514
IP_20250628
CJC-1295 / Ipamorelin Peptide Blend
The combination of CJC-1295, a growth hormone releasing hormone (GHRH) analog, and Ipamorelin, a selective growth hormone secretagogue (GHS), has become a subject of interest in peptide research. This formulation has No DAC. This peptide blend is studied for its synergistic ability to modulate growth hormone secretion and impact downstream biological pathways. All information provided here is for research purposes only and does not constitute medical advice or treatment recommendations.
Chemical Structure
CJC-1295 is a synthetic peptide with a structure designed to increase the half-life of growth hormone releasing hormone analogs through bioconjugation to serum albumin. It contains modifications that enhance its stability compared to endogenous GHRH.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that mimics ghrelin’s action at the ghrelin receptor (GHSR-1a) but is selective for growth hormone release without significant activity on cortisol or prolactin.
Mechanism of Action
When studied together, CJC-1295 and Ipamorelin act through complementary pathways:
CJC-1295 binds to GHRH receptors in the anterior pituitary, stimulating the natural pulsatile release of growth hormone (GH).
Ipamorelin binds to the ghrelin receptor (GHSR-1a), further amplifying GH secretion without significantly influencing other endocrine axes.
The combination supports a more consistent and synergistic elevation of GH, leading to downstream increases in insulin-like growth factor 1 (IGF-1).
Potential Research Benefits
Research suggests that modulation of the GH/IGF-1 axis may have implications for studies in muscle physiology, metabolic regulation, and tissue repair. Preclinical and early clinical findings indicate potential for supporting investigations into:
Improved lean body mass and protein synthesis
Enhanced recovery and cellular repair mechanisms
Age-related changes in growth hormone secretion
While these findings are promising, it is important to emphasize that these compounds are strictly for laboratory and scientific research. No therapeutic claims or dosing recommendations are made.
Selected Research References
CJC-1295 pharmacokinetics and growth hormone/IGF-1 stimulation (PubMed)
Ipamorelin as a selective growth hormone secretagogue (PubMed)
Disclaimer
All content provided on this page is for educational and research purposes only. CJC-1295, Ipamorelin, and their blends are not approved for human consumption. This material is not intended to diagnose, treat, cure, or prevent any disease.
Research Use Only & FDA Disclaimer
Supplier Status
Pure Tested Peptides is a chemical supplier. Pure Tested Peptides is not a compounding pharmacy or chemical compounding facility as defined underSection 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under Section 503B of the same Act.
Use Restrictions
Products are for laboratory research by qualified professionals only.
Products are not drugs, not medical devices, and not cosmetics.
Products must not be used for ingestion, injection, inhalation, implantation, or topical application to humans or animals.
Purchasers are responsible for handling, storage, and disposal in accordance with all applicable laws and safety guidelines.
By purchasing from PureTestedPeptides.com, you acknowledge and agree to these terms of use and restrictions.